| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4221492 | Clinical Imaging | 2015 | 5 Pages |
Abstract
Background18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has proven to be of substantial benefit in imaging of sarcoma patients. We therefore investigated the feasibility and benefit of combined PET/magnetic resonance imaging (MRI).MethodsTwelve patients with sarcoma who underwent FDG PET/MRI for staging and response assessment after chemotherapy were included.ResultsBased on contrast-enhanced MRI and application of Choi criteria, therapy response was classified as stable disease in 6/12 patients (50%) and as partial remission in 6/12 patients (50%).ConclusionIn sarcoma patients, response assessment using Choi criteria based on contrast-enhanced MRI in comparison to FDG PET imaging only demonstrates slight correlation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Markus Kajo Schuler, Ivan Platzek, Bettina Beuthien-Baumann, Michael Fenchel, Gerhard Ehninger, Jörg van den Hoff,